Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Janda M, et al. Among authors: armes je. Gynecol Oncol. 2021 Apr;161(1):143-151. doi: 10.1016/j.ygyno.2021.01.029. Gynecol Oncol. 2021. PMID: 33762086 Free article. Clinical Trial.
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151].
Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Brennan D, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, GraemeWalker, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Janda M, et al. Among authors: armes je. Gynecol Oncol. 2021 Aug;162(2):526. doi: 10.1016/j.ygyno.2021.05.016. Epub 2021 May 28. Gynecol Oncol. 2021. PMID: 34053746 Free article. No abstract available.
Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Hawkes AL, Quinn M, Gebski V, Armes J, Brennan D, Janda M; feMME Trial Committee; Obermair A. Hawkes AL, et al. Contemp Clin Trials. 2014 Sep;39(1):14-21. doi: 10.1016/j.cct.2014.06.014. Epub 2014 Jul 1. Contemp Clin Trials. 2014. PMID: 24999075 Clinical Trial.
ER and PR expression and survival after endometrial cancer.
Smith D, Stewart CJR, Clarke EM, Lose F, Davies C, Armes J, Obermair A, Brennan D, Webb PM, Nagle CM, Spurdle AB. Smith D, et al. Gynecol Oncol. 2018 Feb;148(2):258-266. doi: 10.1016/j.ygyno.2017.11.027. Epub 2017 Dec 6. Gynecol Oncol. 2018. PMID: 29217139
Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis.
Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PM; Astralian National Endometrial Cancer Study Group; Astralian Ovarian Cancer Study Group. Nagle CM, et al. Eur J Nutr. 2013 Mar;52(2):705-15. doi: 10.1007/s00394-012-0376-7. Epub 2012 May 22. Eur J Nutr. 2013. PMID: 22648201 Review.
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, Roche DK, Kennedy C, Chetty NP, Crandon AJ, Flatley C, Oliveira NB, Shannon CM, deFazio A, Tinker AV, Gilks CB, Gabrielli B, Brennan DJ, Coward JI, Armes JE, Perrin LC, Hooper JD. Harrington BS, et al. Among authors: armes je. Br J Cancer. 2016 Feb 16;114(4):417-26. doi: 10.1038/bjc.2015.471. Epub 2016 Feb 4. Br J Cancer. 2016. PMID: 26882065 Free PMC article.
108 results